Could cause temporary or reversible harm; serious harm is unlikely.
Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
| Brand name | GEMCITABINE |
| Generic name | GEMCITABINE |
| Active ingredient(s) | GEMCITABINE HYDROCHLORIDE |
| Distributed by / for | Hikma, Berkeley Heights, NJ 07922 |
| NDC | 0143-9341-01 |
| Full product label | Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01 |
| Recalling firm | McKesson |
| Distribution | Nationwide within the United States |
| Quantity | 74 units |
| Recall initiated | 2026-06-10 |
| Report date | 2026-07-08 |
| Recall completed | — |
| Recall number | D-0714-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Irving TX United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗